Dr. Petrylak on the Results of the Phase II STRIDE Study

Video

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

Daniel P. Petrylak, MD, Professor of Medicine (Medical Oncology) and of Urology, Professor and Co-Director, Signal Transduction Research Program, Yale Cancer Center, discusses results from the phase II STRIDE study.

The randomized STRIDE study evaluated concurrent versus sequential enzalutamide in combination with sipuleucel-T for the treatment of patients with metastatic castration-resistant prostate cancer.

There was no difference seen in immune parameters when comparing early and delayed enzalutamide. Further, Petrylak said, the prime-boost effect was similar in the two arms.

Anecdotally, Petrylak said, no additive or synergistic toxicities were observed. Full toxicity data will be reported later.

<<<

View more from the 2014 ESMO Congress

Related Videos
Minesh Mehta, MD
Ruben Olivares, MD
Phillip J. Koo, MD
Daniel Spratt, MD
Daniel Spratt, MD
Philip J. Koo, MD
Patrick I. Borgen, MD
Anthony D'Amico MD, PhD
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania